Intellia and ONK to collaborate

Tuesday 15 February 2022


Intellia Therapeutics Inc is to out-license rights to its ex vivo Crispr/Cas9 genome editing platform to ONK Therapeutics Ltd enabling the Irish company to develop engineered natural killer (NK) cell therapies for cancer. ONK is developing off-the-shelf NK cell therapies. In addition to the genome editing platform, ONK will also have access to the US company’s lipid nanoparticle delivery technologies. The agreement will enable the development of up to five allogeneic NK cell therapies.